Back to results
US 7,745,428 B2Granted
Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
AssigneeAstraZeneca AB
InventorsDavid Andrews, Andrew John Barker, Maurice Raymond Finlay, Clive Green, Clifford Jones
Life of this patent
Estimating the term…
Abstract
Compounds of formula (I): which possess cell-cycle inhibitory activity are described.
Claims14
A compound of formula (I):
- wherein:
- R1 is selected from halo, amino, C1-3alkyl, C1-3alkoxy, N—(C1-3alkyl)amino, N,N—(C1-3alkyl)2amino and a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom;
- m is 0-4;
- wherein the values of R1 may be the same or different;
- R2 is selected from hydrogen, halo, amino, C1-3alkyl and C1-3alkoxy;
- R3 is hydrogen or halo;
- R4 is hydrogen, ethynyl, halo, cyano, hydroxy, amino, mesyl, trifluoromethyl, trifluoromethoxy, methyl, ethyl or methoxy;
- Ring A is a nitrogen linked 4-7 membered saturated ring which optionally contains an additional nitrogen, oxygen or sulphur atom;
- wherein if said ring contains an additional nitrogen atom that nitrogen may be optionally substituted by R6;
- R5 is a substituent on carbon and is selected from halo, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, sulphamoyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkanoyl, N—(C1-6alkyl)carbamoyl, N,N—(C1-6alkyl)2carbamoyl, C1-6alkylS(O)a wherein a is 0 to 2, C1-6alkoxycarbonyl, N—(C1-6alkyl)sulphamoyl and N,N—(C1-6alkyl)2sulphamoyl;
- wherein R5 independently may be optionally substituted on carbon by one or more R7;
- or R5 is —NHR8, —NR9R10 or —O—R11;
- n is 0-4;
- wherein the values of R5 may be the same or different;
- R6 is selected from C1-6alkyl, C1-6alkanoyl, C1-6alkylsulphonyl, C1-6alkoxycarbonyl, carbamoyl, N—(C1-6alkyl)carbamoyl and N,N—(C1-6alkyl)carbamoyl;
- wherein R6 may be optionally substituted on carbon by one or more R12;
- R8, R9, R10 R11 are independently selected from C1-4alkyl, C1-4alkanoyl, C1-4alkylsulphonyl, C2-4alkenylsulphonyl, C2-4alkynylsulphonyl, C1-4alkoxycarbonyl, carbamoyl, N—(C1-4alkyl)carbamoyl, N,N—(C1-4alkyl)carbamoyl, carbocyclyl and heterocyclyl;
- wherein R8, R9, R10 and R11 may be independently optionally substituted on carbon by a group selected from R13;
- and wherein if said heterocyclyl contains an —NH— moiety that nitrogen may be optionally substituted by R14;
- R13 is selected from halo, cyano, hydroxy, amino, trifluoromethyl, trifluoromethoxy, C1-3alkyl and C1-3alkoxy;
- R14 is selected from C1-3alkyl, C1-3alkanoyl, C1-3alkylsulphonyl, C1-3alkoxycarbonyl, carbamoyl, N—(C1-3alkyl)carbamoyl and N,N—(C1-3alkyl)carbamoyl;
- and
- R7 and R12 are independently selected from halo, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxy, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl and N-methyl-N-ethylsulphamoyl;
- or a pharmaceutically acceptable salt thereof.
21 more elements
A compound of formula (I):
- wherein
- m is 0;
- R2 is selected from hydrogen or methyl;
- R3 is hydrogen;
- R4 is hydrogen, fluoro or methyl;
- Ring A is pyrrolidin-1-yl, 4-methylpiperazin-1-yl, 4-methylhomopiperazin-1-yl or 4-isopropylhomopiperazin-1-yl or morpholino;
- R5 is a substituent on carbon and is dimethylamino;
- n is 0 or 1;
- or a pharmaceutically acceptable salt thereof.
6 more elements
A compound of formula (I):
- selected from:
- [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
- [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
- [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
- [2-fluoro-4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-piperazin-1-yl)-methanone;
- [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-morpholin-4-yl-methanone;
- [2-fluoro-4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-morpholin-4-yl-methanone;
- ((S)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- ((S)-3-dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- ((S)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone;
- ((R)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- ((R)-3-dimethylamino-pyrrolidin-1-yl)-[2-fluoro-4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-methanone;
- ((R)-3-dimethylamino-pyrrolidin-1-yl)-[4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-2-methyl-phenyl]-methanone;
- [4-(4-imidazo[1,2-a]pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-(4-methyl-[1,4]diazepan-1-yl)-methanone;
- {4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-(4-methyl-piperazin-1-yl)-methanone;
- (4-methyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylaminol]-phenyl}-methanone;
- ((S)-3-dimethylamino-pyrrolidin-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone;
- and
- (4-isopropyl-[1,4]diazepan-1-yl)-{4-[4-(2-methyl-imidazo[1,2-a]pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-methanone;
- or a pharmaceutically acceptable salt thereof.
17 more elements
Dependencies are inferred from the claim text.